[PDF] Drugs For Less eBook

Author : Michael P. Cecil, M.D.
Publisher : National Geographic Books
Page : 0 pages
File Size : 11,51 MB
Release : 2005-04-19
Category : Health & Fitness
ISBN : 1578261929

GET BOOK

The first easy-to-use reference guide to saving 50% or more on the 250 most commonly prescribed medications in the United States. Over 40 million Americans lack health insurance. Another 40 million Americans are insured by Medicare and do not have prescription medications as a covered benefit. The 50 million covered by Medicaid are threatened by reduced benefits and limited formulary coverage. Even the 74 million Baby Boomers with health insurance are impacted, as pharmaceutical companies pass their costs on in the form of higher co-pays and insurance premiums. We all are affected by the problem of rising prescription drug costs. Drugs for Less is the answer to the problem. Empowering consumers with needed information, the book outlines seven simple strategies to reduce rising pharmaceutical prices. Here, for example, are tips on how to ensure that drugs you buy online are safe, guidelines on how to slice medications, and information on which generic drugs are more effective than the expensive brand-name versions. Most importantly, the book includes an extensive directory of the 250 most commonly prescribed medications with specific information on how to save money on that drug. Making sense of the convoluted system of pricing drugs and showing you how to beat it, Drugs for Less is the best investment you can make in your health. Visit www.drmichael.com for more information.

Author : Stephen Hyde
Publisher : Bantam
Page : 177 pages
File Size : 36,52 MB
Release : 2009-10-07
Category : Reference
ISBN : 0307480909

GET BOOK

If you want to save up to 50, 70, even 90% on your prescription drug costs, this is the book you need. Stephen S. S. Hyde, founder of Hyde Rx Services Corporation, is the leading authority on low-cost prescription drug benefits, and now he’s offering individual consumers the expertise he provides to America’s employers and health plans. With the simple, cost-saving techniques outlined in this revolutionary book, you can save literally hundreds, even thousands of dollars on your family’s prescription medications. You’ll discover: • The seven questions you should ask your doctor before he writes a prescription • How your pharmacist can save you money • How to get FREE prescription drugs • How to save on generic, over-the-counter, and brand-name drugs • How to get the lowest prices from retail, mail-order, online, and Canadian pharmacies • How you may be eligible for discount cards and other assistance programs • A Special Seniors Medicare Drug Benefit Report, and much more! With an appendix of directories, pharmacies, and websites to get you started, this book will pay for itself with your very first prescription!

Author : Phil Philcox
Publisher : Citadel Press
Page : 276 pages
File Size : 49,76 MB
Release : 2003
Category : Health & Fitness
ISBN : 9780806524993

GET BOOK

This is an essential resource that enables the uninsured to save thousands ofdollars on medications.

Author : Stephen Hyde Hyde
Publisher :
Page : pages
File Size : 48,17 MB
Release : 2009
Category :
ISBN :

GET BOOK

If you want to save up to 50, 70, even 90% on your prescription drug costs, this is the book you need. Stephen S. S. Hyde, founder of Hyde Rx Services Corporation, is the leading authority on low-cost prescription drug benefits, and now he's offering individual consumers the expertise he provides to America's employers and health plans. With the simple, cost-saving techniques outlined in this revolutionary book, you can save literally hundreds, even thousands of dollars on your family's prescription medications. You'll discover:- The seven questions you should ask your doctor before he writes a prescription - How your pharmacist can save you money - How to get FREE prescription drugs - How to save on generic, over-the-counter, and brand-name drugs - How to get the lowest prices from retail, mail-order, online, and Canadian pharmacies - How you may be eligible for discount cards and other assistance programs - A Special Seniors Medicare Drug Benefit Report, and much more!With an appendix of directories, pharmacies, and websites to get you started, this book will pay for itself with your very first prescription!From the Trade Paperback edition.

Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 175 pages
File Size : 48,92 MB
Release : 2019-06-16
Category : Medical
ISBN : 0309486483

GET BOOK

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.

Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 483 pages
File Size : 30,11 MB
Release : 2017-09-28
Category : Medical
ISBN : 0309459575

GET BOOK

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

Author :
Publisher : DIANE Publishing
Page : 380 pages
File Size : 30,2 MB
Release : 1993
Category : Drugs
ISBN : 9780788104688

GET BOOK

Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.

Author : Institute of Medicine
Publisher : National Academies Press
Page : 377 pages
File Size : 16,39 MB
Release : 2013-06-20
Category : Medical
ISBN : 0309269393

GET BOOK

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

Author : Zaheer-Ud-Din Babar
Publisher : Academic Press
Page : 240 pages
File Size : 22,7 MB
Release : 2018-02-27
Category : Medical
ISBN : 0128119624

GET BOOK

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines. Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs Incorporates existing guidelines and recommendations by international organizations Compares and contrasts how different countries fund and police high-cost drug access Explores novel and emergent policies, including managed entry agreement, analysis of real world data and differential pricing Reviews novel pharmaceuticals of current research interest